Editorial Comment on “Muscle-Invasive Bladder Cancer Treatment Selection in an Emerging Treatment Era: A Patient Preference Study”
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder CancerNew England Journal of Medicine, 2024
- Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysisThe Lancet Oncology, 2023
- Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial CarcinomaNew England Journal of Medicine, 2021